期刊
SCIENCE
卷 369, 期 6504, 页码 718-+出版社
AMER ASSOC ADVANCEMENT SCIENCE
DOI: 10.1126/science.abc6027
关键词
-
资金
- Fonds IMMUNOV, for Innovation in Immunopathology
- Institut National de la Sante et de la Recherche Medicale (INSERM)
- Agence National de la Recherche as part of the Investment for the Future program [ANR-10-IAHU-01]
- Agence National de la Recherche (ANR-flash Covid19 AIROCovid)
- Agence National de la Recherche (ANR-flash Covid19 CoVarImm)
- Institut Imagine M.D.-Ph.D. fellowship program by Fondation Bettencourt Schueller
- FAST Foundation (French Friends of Sheba Tel Hashomer Hospital)
- EUR G.E.N.E. program of the Universite de Paris - French Government through its Investments for the Future program [ANR-17-EURE-0013, IdEx ANR-18-IDEX-0001]
- Agence National de la Recherche as part of the Investment for the Future program (Laboratoire d'Excellence Milieu Interieur) [ANR-10-LABX-69-01]
- Institut Pasteur
- Agence Nationale de la Recherche (ANR) [ANR-17-EURE-0013] Funding Source: Agence Nationale de la Recherche (ANR)
Coronavirus disease 2019 (COVID-19) is characterized by distinct patterns of disease progression that suggest diverse host immune responses. We performed an integrated immune analysis on a cohort of 50 COVID-19 patients with various disease severity. A distinct phenotype was observed in severe and critical patients, consisting of a highly impaired interferon (IFN) type I response (characterized by no IFN-beta and low IFN-alpha production and activity), which was associated with a persistent blood viral load and an exacerbated inflammatory response. Inflammation was partially driven by the transcriptional factor nuclear factor-kappa B and characterized by increased tumor necrosis factor-alpha and interleukin-6 production and signaling. These data suggest that type I IFN deficiency in the blood could be a hallmark of severe COVID-19 and provide a rationale for combined therapeutic approaches.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据